AIDS Associated Dementia - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 26 Pages - SKU: GMD6776012
|
|
AIDS Associated Dementia - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'AIDS Associated Dementia - Pipeline Review, H1 2012', provides an overview of the AIDS Associated Dementia therapeutic pipeline. This report provides information on the therapeutic development for AIDS Associated Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS Associated Dementia. 'AIDS Associated Dementia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for AIDS Associated Dementia.
- A review of the AIDS Associated Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the AIDS Associated Dementia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for AIDS Associated Dementia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding AIDS Associated Dementia pipeline depth and focus of AIDS Associated Dementia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- AIDS Associated Dementia Overview
- Therapeutics Development
- An Overview of Pipeline Products for AIDS Associated Dementia
- AIDS Associated Dementia Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- AIDS Associated Dementia Therapeutics - Products under Investigation by Universities/Institutes
- AIDS Associated Dementia - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Zidovudine + Didanosine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Didanosine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Memantine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Fluconazole - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Paroxetine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AIDS Associated Dementia Therapeutics - Discontinued Products
- AIDS Associated Dementia Therapeutics - Dormant Products
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for AIDS Associated Dementia, H1 2012
- Products under Development for AIDS Associated Dementia - Comparative Analysis, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- AIDS Associated Dementia Therapeutics - Discontinued Products
- AIDS Associated Dementia Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for AIDS Associated Dementia, H1 2012
- Products under Development for AIDS Associated Dementia - Comparative Analysis, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
